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Ubiquinone binding site of yeast 
NADH dehydrogenase revealed 
by structures binding novel 
competitive- and mixed-type 
inhibitors
Tetsuo Yamashita1, Daniel Ken Inaoka2,3, Tomoo Shiba4, Takumi Oohashi2, So Iwata5,6,7,8,9, 
Takao Yagi10, Hiroaki Kosaka1,12, Hideto Miyoshi11, Shigeharu Harada4, Kiyoshi Kita2,3 & 
Katsuya Hirano  1
Yeast Ndi1 is a monotopic alternative NADH dehydrogenase. Its crystal structure in complex with 
the electron acceptor, ubiquinone, has been determined. However, there has been controversy 
regarding the ubiquinone binding site. To address these points, we identified the first competitive 
inhibitor of Ndi1, stigmatellin, along with new mixed-type inhibitors, AC0-12 and myxothiazol, and 
thereby determined the crystal structures of Ndi1 in complexes with the inhibitors. Two separate 
binding sites of stigmatellin, STG-1 and STG-2, were observed. The electron density at STG-1, located 
at the vicinity of the FAD cofactor, further demonstrated two binding modes: STG-1a and STG-1b. 
AC0-12 and myxothiazol are also located at the vicinity of FAD. The comparison of the binding modes 
among stigmatellin at STG-1, AC0-12, and myxothiazol revealed a unique position for the aliphatic 
tail of stigmatellin at STG-1a. Mutations of amino acid residues that interact with this aliphatic tail at 
STG-1a reduced the affinity of Ndi1 for ubiquinone. In conclusion, the position of the aliphatic tail of 
stigmatellin at STG-1a provides a structural basis for its competitive inhibition of Ndi1. The inherent 
binding site of ubiquinone is suggested to overlap with STG-1a that is distinct from the binding site for 
NADH.
A monotopic alternative NADH dehydrogenase (Type II NADH dehydrogenase: NDH-2) catalyses the electron 
transfer from NADH to quinone via FAD or FMN without a proton-pumping activity, and functions as an initial 
enzyme, either in addition to or as an alternative to proton-pumping NADH dehydrogenase (complex I) in the 
respiratory chain of bacteria, archaea, and fungal and plant mitochondria1–3. NDH-2 has been attracting based 
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on its potential medical applications. A series of studies has suggested that Ndi1, one of three NDH-2s from 
Saccharomyces cerevisiae, would be useful in replacement therapy for mitochondrial diseases caused by com-
plex I dysfunction4–7. Apoptosis-inducing factor (AIF) and its family member protein AIF-M2 are mammalian 
members of NDH-2 family8,9. Although they exert NADH-ubiquinone oxidoreductase activity under certain 
conditions8, their functional role as a NADH-ubiquinone oxidoreductase in the respiratory chain is dispensable 
in mammals, as complex I plays a major role. Therefore, the microorganism NDH-2 has emerged as a potential 
therapeutic target for drugs targeting human pathogenic bacteria10–13 and parasites14–16. The quinone binding 
site of NDH-2 is thought to be an ideal target for chemotherapeutic agents because several compounds showing 
highly selective toxicity for parasites have been shown to target the quinone binding of respiratory enzymes17–19. 
Atovaquone, which has a similar structure to ubiquinone, is used as a therapeutic agent for Plasmodium falciparum 
malaria. It inhibits the respiration of malaria parasites by inhibiting the binding of ubiquinone to complex III20. 
The biochemical and structural basis for the function of NDH-2 has been intensively studied for these purposes 
in recent years10–12,14–16.
We reported that the enzymatic reaction of yeast Ndi1 has a ping-pong mechanism, as is the case with 
NDH-2s from Mycobacterium tuberculosis and Yarrowia lipolytica21–23. In this reaction mechanism, two sub-
strates—NADH and ubiquinone—bind to the enzyme sequentially, but not at the same time. However, our pre-
vious study could not determine whether the reaction occurred via a one-site or two-site ping-pong mechanism. 
Recent studies that investigated the structure and biochemistry of NDH-2s proposed a non-classical two-site 
ping-pong mechanism in M. tuberculosis NDH-224 and a ternary complex mechanism in yeast Ndi125 and NDH-2 
from Staphylococcus aureus26. NDH-2 from Caldalkalibacillus thermarum follows either a two-site ping-pong 
mechanism or a ternary complex mechanism depending on the substrate that is used27. NADPH favoured a 
two-site ping-pong mechanism, while NADH favoured a ternary complex mechanism27. In a ternary complex 
mechanism, two substrates—NADH and ubiquinone—simultaneously bind to the enzyme. Thus, these two reac-
tion mechanisms require separate binding sites for NADH and ubiquinone.
We previously determined the crystal structure of Ndi1 in complex with either NAD+ or ubiquinone and 
demonstrated that the binding sites of both substrates overlap with each other and that the bound ubiqui-
none penetrates the plane of the isoalloxazine ring of FAD (Fig. 1A)28; these observations support the one-site 
ping-pong mechanism. In contrast, the structure of Ndi1 reported by Feng et al. proposed the presence of two 
ubiquinone binding sites (UQI and UQII), both of which were located on the opposite side of the NADH binding 
site with respect to the plane of the isoalloxazine ring of FAD (Fig. 1B,C)29. This structural model is consistent 
with either a two-site ping-pong mechanism or a ternary complex mechanism. Thus, in order to understand the 
enzymatic mechanism of Ndi1, it is necessary to elucidate the reason for the inconsistency in the reported binding 
site of ubiquinone. One insightful strategy that could solve this problem would be to elucidate the crystal struc-
tures of Ndi1 in complex with a competitive inhibitor and to identify the site responsible for competitive inhibi-
tion, because the site contributing to the binding of a competitive inhibitor might also be involved in the binding 
of substrate ubiquinone. However, while many compounds, including phenothiazines and quinolones, are known 
to be inhibitors of NDH-2, no competitive inhibitor has been identified for NDH-210,14,15,21,30.
In the present study, we screened the compounds that are known to inhibit quinone binding in several res-
piratory enzymes, including NDH-2, and thereby discovered the first competitive inhibitor of Ndi1, stigmatellin. 
Furthermore, AC0-12 and myxothiazol were newly identified as mixed-type inhibitors of Ndi1. The comparison 
of the crystal structures of Ndi1 in complexes with stigmatellin, AC0-12, and myxothiazol, revealed a unique 
binding site for stigmatellin that was distinct from the binding site for NADH. Mutations of amino acid residues 
that are involved in specific binding to stigmatellin reduced the affinity of Ndi1 for ubiquinone. As a result, we 
propose that the binding site of stigmatellin may be the binding site of the substrate ubiquinone.
Results
The identification of stigmatellin as a competitive inhibitor of Ndi1. The compounds that have 
been shown to inhibit quinone binding in several respiratory enzymes (including complex I, II and III, cya-
nide-insensitive alternative oxidase, and NDH-2) and their derivative compounds were screened to find novel 
competitive inhibitors for yeast Ndi1. First, the compounds that inhibited the NADH-ubiquinone-1 oxidore-
ductase activity of Ndi1 by >70% at a concentration of 10 μM were selected. Second, the compounds for which 
the IC50 values for the inhibition of the Ndi1 activity were <1 μM were selected, and the mode of ubiquinone 
inhibition was investigated for all of the selected compounds. Four inhibitors, including a quinolone deriva-
tive, 1-hydroxy-2-dodecyl-4(1 H) quinolone (AC0-12), and compounds with carbon skeletons that differed from 
quinolone, stigmatellin, myxothiazol, and ascochlorin (Fig. 2A), were newly found (Table 1). Notably, stigmatel-
lin (IC50 = 107 ± 21 nM) and AC0-12 (IC50 = 115 ± 18 nM) exhibited higher potency than 1-hydroxy-2-unde-
cyl-4(1 H) quinolone (AC0-11), the most potent inhibitor of Ndi1 (IC50 = 200 nM) ever identified23.
A Lineweaver-Burk plot analyses (Fig. 2B–E) indicated that stigmatellin is a competitive inhibitor whereas the 
others are mixed-type (Table 1). This was further corroborated by the Ki and α values obtained by fitting the data 
to the equation of mixed model inhibition in the Prism6 software program (Table 1). The product αKi provides a 
dissociation constant for ternary enzyme-substrate-inhibitor complex31. The α value of stigmatellin was estimated 
to be close to infinity, which indicated the competitive nature of the inhibition of the Ndi1 oxidoreductase activity 
by stigmatellin. On the other hand, the finite and greater-than-one α values of other compounds were consistent 
with their inhibition of the Ndi1 oxidoreductase activity being of the mixed type.
Structure determination. Ndi1-stigmatellin, -AC0-12 and -myxothiazol complexes were successfully 
crystallized by cocrystallization, but diffraction-quality crystals of the Ndi1-ascochlorin complex could not be 
obtained. The dimer structures of the Ndi1-stigmatellin, -AC0-12 and -myxothiazol complexes were determined 
at resolutions of 1.85 Å, 3.4 Å, and 3.2 Å, respectively, by molecular replacement using the inhibitor-free Ndi1 
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structure (PDB code: 4G9K) as a template (Supplementary Table S1). In the crystals of the Ndi1-AC0-12 and 
-myxothiazol complexes there is one dimer in each asymmetric unit, whereas protomers of the Ndi1-stigmatellin 
dimer are related by a crystallographic two-fold axis. There are no significant differences between the structures 
of the complexes, as indicated by root-mean-square deviations of 0.58–0.76 Å, which were calculated for 454–462 
superimposed Cα positions.
Two stigmatellin binding sites. Two stigmatellin molecules, STG-1 and STG-2 are bound to the hydro-
phobic surface of the membrane-anchor region of Ndi1 (Fig. 3A,B). STG-1 is located at the si-face of the adja-
cent FAD cofactor in the cavity formed by the C-terminal α15 helix and the β19-21 sheets of Ndi1 (Figs 1D 
and 3C). This cavity has been proposed to serve as a ubiquinone binding site based on the structures of the 
Ndi1-ubiquinone complex (PDB codes: 4GAV and 4G74) by our group28 and by Feng et al.29 (Fig. 3D).
The electron density of the STG-1 demonstrates that the inhibitor is bound to the enzyme in two distinct bind-
ing modes, STG-1a and STG-1b (site 1 in Fig. 4A). The aromatic head groups of the STG-1a and STG-1b overlap 
each other, while the aliphatic tails extend to different directions. The aromatic head groups of the STG-1a and 
STG-1b form hydrogen bonds with the isoalloxazine ring of the FAD cofactor (Fig. 4E) and are surrounded by 
Figure 1. The arrangement of inhibitors and substrates in relation to the si- and re-face of the FAD cofactor. The 
re-face and si-face (membrane side) of the isoalloxazine ring of FAD are separated by the dashed line. The substrate 
molecules, NAD+, UQ, UQI, and UQII are represented by yellow, orange, magenta, and pink sticks, respectively. 
(A) The binding model of NAD+ and ubiquinone that was proposed in our previous report28. The structures of the 
Ndi1-NAD+ (PDB code: 4GAP) and Ndi1-ubiquinone (PDB code: 4GAV) complexes are superposed to adapt this 
model. (B and C) The binding model of NAD+ and ubiquinone proposed by Feng et al.29. The structures of Ndi1-
NAD+-ubiquinone (PDB code: 4G73; b) and Ndi1-ubiquinone (PDB code: 4G74; C) complexes are superposed to 
adapt this model. (D–F) The inhibitors, stigmatellins (STG-1a and -1b, D), AC0-12 (E) and myxothiazol (MYX, F), 
are represented by as aqua, green, hot pink and blue sticks, respectively.
www.nature.com/scientificreports/
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W63, P92, A393, Q394, H397, A446, L447, Y482, M485, and L487 (site 1 in Figs 4A and 5). The aliphatic tail of 
STG-1a interacts with L444, I459, R460, and S461, whereas that of STG-1b interacts with S484 (site 1 in Fig. 4A). 
In contrast, STG-2 is bound to a groove formed by helixes α15 and α16 in the C terminal membrane-anchor 
domain of Ndi1 (Fig. 3A–C). The head group of the STG-2 is demonstrated by well-defined electron density, and 
it is lined by F475, Y476, R479, and I480 (site 2 in Fig. 4A) and formed the hydrogen bond with R479 (Fig. 4F), 
which is relatively conserved among different species (Fig. 5).
Figure 2. The inhibitory effects of stigmatellin, AC0-12, myxothiazol and ascochlorin on the NADH-
ubiquinone oxidoreductase activity of the recombinant Ndi1. (A) The chemical structures of the inhibitors. 
(B–E) Lineweaver-Burk plots for the NADH-ubiquinone oxidoreductase activity obtained with various 
concentrations of ubiquinone-1 and 100 μM NADH, in the presence of stigmatellin, AC0-12, myxothiazol, 
and ascochlorin at the indicated concentrations in nM. The data are from the triplicate measurements of one 
representative assay. Three independent assays gave similar results.
www.nature.com/scientificreports/
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AC0-12 and myxothiazol binding sites. In the structures of Ndi1-AC0-12 and Ndi1-myxothiazol complexes, 
AC0-12 and myxothiazol molecules are bound to a site that is identical to that of STG-1 (Fig. 3C). The hydrocarbon tail 
region (C8-C12) of AC0-12 in the Ndi1-AC0-12 complex has an extremely low electron density; thus, while the rest 
of the AC0-12 molecule can be observed, the hydrocarbon tail region cannot. The bound AC0-12 molecule is located 
in the vicinity of the si-face of the FAD isoalloxazine ring (Figs 1E and 4B) and forms hydrogen bonds with Q394 
(Supplementary Fig. S1), which is relatively conserved across the amino acid sequences of various species (Fig. 5). The 
residues (Q394, H397, A446, Y482, and M485), which form the binding cavity of AC0-12 (Fig. 4B), are also involved 
in the binding site of the head group of the STG-1 (Figs 4D and 5). On the other hand, the electron density corre-
sponding to myxothiazol extends from the si-face to the re-face of the FAD isoalloxazine ring (Figs 1F and 4C). The 
bithiazole group of myxothiazol is located adjacent to FAD and forms hydrogen bonds with the FAD isoalloxazine 
ring (Supplemental Fig. S1). This configuration is similar to that observed in the Ndi1-ubiquinone structure, which we 
described previously28 (Fig. 1A vs. 1F). The binding cavity of myxothiazol is constructed by 10 residues: W63, P238, 
M280, P390, T392, Q394, H397, A446, L447, and M485 (Fig. 4C), six of which (W63, Q394, H397, A446, L447, and 
M485) are also found among the residues lining the cavity for the head group of stigmatellin at the STG-1 site; four 
residues (P238, M280, P390, and T392) are specific to myxothiazol (Figs 4D and 5).
In summary, the aforementioned 10 residues that interact with the aromatic head group of STG-1a and 
STG-1b include the residues that interact with mixed-type inhibitors, AC-012 and myxothiazol, while 4 addi-
tional residues (P238, M280, P390, and T392) are specific for the interaction with myxothiazol. This large overlap 
reflects the observation that stigmatellin at the STG-1 site and the mixed-type inhibitors overlap near the FAD 
cofactor (Fig. 6A). In contrast, the residues that interact with the aliphatic tail of STG-1a and STG-1b and the 
residues that interact with STG-2 are specific for the interaction with stigmatellin.
Kinetic analyses of the mutant enzymes. The comparative study on the modes of binding between stig-
matellin at the STG-1a and STG-1b sites, AC0-12, and myxothiazol, allows us to recognize a unique structure of the 
aliphatic tail of stigmatellin at the STG-1a site (Fig. 6A). This unique structure appears to be related to the competitive 
nature of the inhibition of Ndi1 oxidoreductase activity by stigmatellin. It is therefore hypothesized that L444, I459, 
R460, and S461, which interact with stigmatellin at the STG-1a site, are also involved in the binding of the substrate 
ubiquinone (Fig. 5). This hypothesis was evaluated by examining the effects of mutations of the proximal L444 and I459 
on the kinetics of the enzymatic reaction of Ndi1. The effect of the mutation of S484, which specifically interacts with 
stigmatellin at the STG-1b site, was examined as a control. Furthermore, the effects of mutations of W63, P92, A393, 
Q394, H397, L447, Y482, M485, and L487, which interact with the aromatic head group of stigmatellin at the STG-1a 
and STG-1b sites, were also examined. Moreover, to investigate the functional role of the STG-2 site in ubiquinone 
binding, a mutation was also introduced to R479. The wild-type and 22 mutated Ndi1 enzymes were expressed and 
purified as recombinant proteins, and their Km and Vmax values for the oxidoreductase reaction were determined using 
ubiquinone-1 as a substrate with NADH at a fixed concentration of 100 μM (Table 2).
Among 5 mutants of L444 and I459, L444D, I459A, and I459W, increased the Km value for ubiquinone-1 
by 1.7-, 1.8-, and 3.3 fold, in comparison to the Km value obtained with the wild-type enzyme, while I459A 
and I459N drastically reduced the Vmax values (Table 2). I459N had a lower influence on the Km value in com-
parison to I459A and I459W, in accordance with the smaller change in the amino acid size. L444N, a similar 
size-conservative mutation, has little effect on the Km and Vmax values.
Among 11 mutants of 9 residues interacting with the aromatic head group of stigmatellin, 5 mutants (W63F, 
A393G, Q394G, H397A, and M485E) increased the Km values by 2.3-, 1.4-, 1.4-, 1.5-, and 2.8 fold, respectively 
(Table 2). The other 6 mutants (P92A, Q394A, L447N, Y482F, M485A, and L487A) had little effect on the Km val-
ues (Table 2). However, the substantial reduction of the Vmax values was observed with P92A (1% of the wild-type 
activity), L447N (13%), and M485A (28%) (Table 2). A partial decrease in the Vmax value was observed with 
Q394G (43%), Q394A (37%), H397A (44%), and L487A (40%) (Table 2). Among them, Q394G and H397A also 
increased the Km values as mentioned previously. In contrast, the significant decrease in the Vmax value was not 
observed with W63F (137%), A393G (83%), and M485E (112%), which increased the Km values (Table 2). Y482F, 
which had little effect on the Km value, also had little effect on the Vmax value (Table 2).
Two mutants of the residue interacting with stigmatellin at the STG-1b site—S484F and S484I—had no effect 
on either the Km or Vmax values. Four mutants of the residue interacting with stigmatellin at the STG-2 site—R479I 
(0.02%), R479A (30%), R479K (29%), and R479H (0.1%)—reduced the Vmax values. R479A and R479K reduced 
the Km values.
Compound IC50a (nM) Inhibition modeb Kic (nM) αc (α > 0)
Stigmatellin 107 ± 21.0 competitive 93.9 ± 30.4 ~6.33×1020
AC0-12 115 ± 18.0 mixed 14.0 ± 1.9 13.0±11.7
Myxothiazol 308 ± 22.9 mixed 48.8 ± 5.2 70.2±192
Ascochlorin 955 ± 139 mixed 728 ± 191 2.64±1.87
Table 1. Inhibitory effects of inhibitors on NADH-ubiquinone-1 oxidoreductase activity of the purified 
Ndi1. aEach value represents the mean ± S.E.M of three independent experiments. bInhibition modes for 
ubiquinone-1 were determined by the intersection point in Lineweaver-Burk plots (Fig. 2B–E). cThe values for 
the inhibition constant Ki and α were determined by fitting the experimental data, which are the same as the 
Lineweaver-Burk plots, to non-linear regression of mixed type inhibition using the GraphPad Prism 6 software 
program. Each value represents the mean ± S.D.
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Figure 3. The binding sites of the inhibitors in the crystal structures of the Ndi1-inhibitor complexes. (A) An 
overall view of the Ndi1 monomer in complex with the FAD cofactor and stigmatellin with the backbone of 
Ndi1 shown in transparent grey. The cavities in the orange surface are shown in parallel to the cross-section 
of the membrane. Three different modes of stigmatellin binding are shown: STG-1a (aqua), STG-1b (green), 
and STG-2 (yellow). (B) A close-up view of stigmatellin binding at three sites in relation to the binding site of 
FAD and the groove formed by the α15 and α16 helixes of Ndi1 (pink). The view in A is rotated by 30° in B. 
(C–E) The view of one dimeric structure of Ndi1 viewed from the membrane-anchor side. The β19-21 sheets 
and the α15 and α16 helixes in Ndi1 forming the cavities for inhibitors are represented by a cartoon model. 
The hydrophobic and hydrophilic surfaces of the dimer are indicated in red and white, respectively. In (C), the 
relative locations of STG-1a, STG-1b, STG-2, AC0-12 (red), and myxothiazol (MYX: blue) are shown in overall 
and close-up views. In (D), the relative locations of UQ (orange), UQI (magenta), and UQII (pale orange) are 
shown in a close-up view. The structures of Ndi1-ubiquinone (PDB codes: 4GAV and 4G74) complexes are 
superposed to adapt this model28,29. In (E), the relative locations of STG-1a, STG-1b, STG-2, hexaethylene glycol 
(P6G: orange), triethylene glycol (PGE: pale orange), and Triton X-100 (TRT: purple) are shown in a close-up 
view. The structure of the substrate-free Ndi1 (PDB code: 4G6G) is superposed to adapt this model29.
www.nature.com/scientificreports/
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Discussion
The present study identified four potent new inhibitors of yeast Ndi1: stigmatellin, AC0-12, myxothiazol, and 
ascochlorin. Stigmatellin, myxothiazol, and ascochlorin have novel carbon skeletons that are different from the 
known inhibitors of quinolone derivatives, including AC0-12. Among them, stigmatellin was determined to 
Figure 4. Amino acid residues contributing to inhibitor binding in Ndi1. (A–C) The residues interacting 
with stigmatellin at site 1 (STG-1a and STG-1b) and site 2 (STG-2) (A), AC0-12 (B), and myxothiazol (C) are 
represented by yellow sticks. The FAD cofactor, glycerol (GOL), triethylene glycol (PGE), hexaethylene glycol 
(P6G), and 2-morpholinoethanesulfonic acid (MES) are represented by pink sticks. The electron density maps 
calculated for inhibitors are represented by blue (1σ level) and orange (2σ level in A and C; 1.5σ level in B) 
nets. Both views are from the membrane-anchor side. (D) The residues interacting with two and three different 
inhibitors in the inhibitor-overlapping region are shown in orange and emerald green, respectively. (E,F) 
The residues contributing to the interaction with stigmatellin molecules by hydrogen bonding. The protein 
backbone is represented by a gray cartoon, with FAD (white), glycerol (GOL: blue), and Arg479 (R479: pale 
orange) molecules. (E) Interaction between the isoalloxazine ring of FAD and STG-1 (STG-1a: aqua; STG-1b: 
green). (F) Interaction between R479 and STG-2 (yellow).
www.nature.com/scientificreports/
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be the first competitive inhibitor against ubiquinone by the kinetic analysis of its effect on the Ndi1-mediated 
oxidoreductase reaction. The comparison of the structures of Ndi1 in complexes with stigmatellin, AC0-12 and 
myxothiazol revealed a unique binding mode of stigmatellin at the STG-1a site, with an aliphatic tail extending in 
a different direction from the other inhibitors. This unique binding of stigmatellin is suggested to be related to the 
competitive nature of its inhibition of Ndi1 oxidoreductase activity. Thus, it is hypothesized that the STG-1a site 
overlaps with the site of ubiquinone binding during the enzymatic reaction. In fact, the STG-1a site overlaps with 
the site of ubiquinone binding that was reported as the UQI site by Feng et al.29. Eight of the ten residues involved 
in the interaction with ubiquinone at UQI are shared by those involved in the interaction with stigmatellin at 
STG-1a (Fig. 5). The mutations of L444 and I459, which specifically interact with the aliphatic tail of stigmatellin 
at the STG-1a site, increased the Km values for ubiquinone when mutations were non-conservative, and there-
fore caused significant changes in the size and charge of the amino acid, as was the case with L444D, I459W, and 
I459A. We propose that the STG-1a site represents the inherent ubiquinone binding site in yeast Ndi1.
The crystallographic analysis of the present study revealed three stigmatellin binding sites: STG-1a, STG-1b, 
and STG-2. STG-2 is not related to any of the reported binding sites of ubiquinone, NADH, or FAD28,29. The 
STG-2 site is more than 15 Å distant from the FAD binding site. Furthermore, the STG-2 site contained not only 
the stigmatellin molecule but also other hydrophobic molecules such as hexaethylene glycol in the cocrystal 
(P6G) (Fig. 3E and site 2 in Fig. 4A). Similarly, the detergent molecules (Triton X-100) were found in the same 
groove in the Ndi1 structure (PDB code: 4G6G) that was reported by Feng et al., (Fig. 3E)29. However, all of the 
mutations of R479, which specifically interact with stigmatellin at the STG-2 site, drastically reduced the Vmax 
Figure 5. Multiple alignment of the amino acid sequences of NDH-2s. The amino acid residues interacting 
with the aromatic head groups of the STG-1a and STG-1b, the aliphatic tail of STG-1a, and the aliphatic tail of 
STG-1b are shown as orange, aqua, and green boxes, respectively. Those interacting with STG-2, AC0-12 and 
myxothiazol are shown as yellow, red, and blue boxes, respectively, in the lanes placed on the top of sequences. 
The amino acids residues interacting with ubiquinone at the UQI and UQII sites in the Ndi1-ubiquinone 
complex structures (PDB code: 4G74) are indicated by purple and pink circles at the bottom of the sequences, 
respectively29. The residues in red and pink indicate those that are conserved among 10-12, and 7-9 species, 
respectively. The alignment was produced from amino acid sequences from Saccharomyces cerevisiae, Ndi1 
(CAA89160.1); Plasmodium falciparum, NDH-2 (XP_001352022.1); Toxoplasma gondii, NDH-2 (ABB17192.1); 
Yarrowia lipolytica, NDH-2 (CAA07265.1), Neurospora crassa, NDE-2 (EAA29772.1); Trypanosoma 
brucei, NDH-2 (XP_823167.1); Trypanosoma cruzi, NDH-2 (XP_812197.1); Arabidopsis thaliana, NDA1 
(NP_563783.1); Solanum tuberosum, NDA1 (CAB52796.1); Rhizobium etli, NDH-2 (AAM54916.2); Escherichia 
coli, NDH-2 (CAA23586.1); and Mycobacterium tuberculosis, NDH-2 (KFZ73195.1).
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value, with no increase in the Km value. Thus, we hypothesize that the binding of stigmatellin at the STG-2 site 
might be non-functional and an artificial observation.
In contrast, STG-1a apparently overlaps with the previously reported ubiquinone binding site, UQI (Fig. 6C), 
while STG-1b overlaps with UQII (Fig. 6D)29. The mutations of the amino acid residues, which interact with the 
aromatic head group that is common to both STG-1a and STG-1b, affected the enzymatic activity of Ndi1 by 
either increasing the Km value or decreasing the Vmax value (with the exception of Y482F). There was a reciprocal 
relationship between the effect on the Km value and that on the Vmax value: a greater increase in the Km value was 
associated with a smaller reduction in the Vmax. Conversely, a greater decrease in the Vmax value was associated 
with a smaller increase in the Km value. M485E and W63F, which caused the greatest increase in the Km value, 
caused no reduction (M485E)—or rather—an increase (W63F) in the Vmax value. In contrast, P92A, L447N, and 
M485A, which caused the greatest decrease in the Vmax value, caused no increase in the Km value. These obser-
vations suggested that W63 and M485 are essential for ubiquinone binding and that P92, L447, and M485 might 
contribute to the Ndi1 activity. Since the aromatic head group of stigmatellin overlapped with the binding site of 
the mixed-type inhibitors, AC0-12 and myxothiazol, the amino acid residues interacting with the aromatic head 
group appear to be responsible for the mixed-type inhibition of the Ndi1 activity. On the other hand, the muta-
tions of the residues specifically interacting with the aliphatic tail of stigmatellin at the STG-1a site increased the 
Km value, when the mutation was non-conservative (L444D, I459W, and I459A). In contrast, the mutations of the 
residues specifically interacting with the aliphatic tail of stigmatellin at the STG-1b site had no effect on either the 
Figure 6. A comparison of the binding of stigmatellin, AC0-12 and myxothiazol to Ndi1, in relation to the 
UQI and UQII sites. (A) Close-up views of the overlap projection of the binding of stigmatellin (STG-1a: aqua; 
STG-1b: green), myxothiazol (blue) and AC0-12 (red) to Ndi1 (transparent gray). (B) A close-up view of 
the ubiquinone at the UQI (transparent pink) and UQII (transparent pale orange) sites, which were adapted 
by superimposing the Ndi1-ubiquinone complex structure (PDB code: 4G74) proposed by Feng et al.29. The 
amino acid residues that form a space for the UQI and UQII sites at the si-face of FAD are shown in transparent 
yellow meshes. (C,D) The overlap projection of ubiquinone in UQI and UQII sites with stigmatellin at STG-1a 
site (C) and stigmatellin at STG-1b, AC0-12 and myxothiazol (D). (E) The predicted UQI site in ubiquinone 
reduction by Ndi1. The structures determined for the Ndi1-stigmatellin, Ndi1-ubiquinone (PDB code: 4G74)29 
and Ndi1-NAD+ complexes (PDB code: 4GAP)28 are superposed. The ubiquinone molecule (magenta) in the 
UQI site and NAD+ molecule (yellow) are located on the si-face and re-face of the isoalloxazine ring of FAD 
(white), respectively. The head group of stigmatellin in both positions of STG-1a (transparent aqua) and STG-1b 
(transparent green), as well as the alkenyl chain of stigmatellin in the position of STG-1a overlaps with the UQI 
site.
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Km or Vmax values, despite the fact that the mutations were non-conservative (S484F, S484I). These observations 
suggest that the STG-1a site, especially the site of the aliphatic tail of stigmatellin—but not the STG-1b site—is 
responsible for the competitive inhibition of Ndi1 by stigmatellin. As a result, the UQI site, which overlaps with 
the STG-1a site (Fig. 6C)—but not the UQII site, which overlaps with the STG-1b site (Fig. 6D)—appears to rep-
resent the site of ubiquinone binding as a substrate during the enzymatic reaction.
As a result, 4 residues (W63, M485, L444, and I459) are suggested to contribute to the ubiquinone binding, 
because their non-conservative mutations consistently increased the Km values. The aromatic character at W63 
has been reported to be highly conserved among NDH-2s (Fig. 5) and suggested to stabilize the prosthetic group 
FAD in the enzyme32. The present study therefore identified a new role in substrate binding for these residues. 
Among the two residues (L444 and I459) that specifically interact with the aliphatic tail of STG-1a, the hydropho-
bicity at I459, but not L444, is conserved among the HDH-2s (Fig. 5).
The identification of ubiquinone binding as a substrate at the STG-1a/UQI site implies that the binding sites 
for two substrates—ubiquinone and NADH—are distinct. This configuration is apparently consistent with either 
(two-site) ping-pong or ternary complex mechanisms of the enzymatic reaction of Ndi123,25. Our previous bio-
chemical studies suggested that the binding sites for ubiquinone and NADH are distinct; thus, a model for the 
enzymatic reaction that was compatible with either two-site ping-pong or ternary complex mechanisms was 
proposed25. However, Feng et al., hypothesized that the binding of ubiquinone at the UQI site functioned as a 
structural component and not as a substrate29,33. Instead, they proposed that the substrate ubiquinone binds to 
the UQII site. In the present study, the mutations of the amino acid residue (S484) that specifically interacts with 
STG-1b, which overlaps with the UQII site, had no effect on the affinity for ubiquinone. The findings of the present 
study therefore support that the STG-1a/UQI site has a role as a site for substrate ubiquinone binding. STG-1b/
UQII may not be functional in the enzymatic reaction of Ndi1. A comparison of the structure of the bacterial 
NDH-234,35 to that of the yeast Ndi1 suggests that the side chain of R382 in bacterial NDH-2 may cause steric hin-
drance of the binding of quinone to the site corresponding to the UQII site in yeast Ndi1. This implies that there is 
only one quinone binding site in the bacterial NDH-2, which corresponds to the UQI site of yeast Ndi1, and that 
the site corresponding to the UQII site is non-functional in the bacterial NDH-2.
Our previous crystallographic study indicated that ubiquinone binds in close vicinity to FAD, penetrating the 
plane of the isoalloxazine ring of FAD with the isoprenoid side chain on the si-face and the quinone ring on the 
re-face (Fig. 1A)28. Since the quinone ring overlapped with NAD+, we discarded the possibility of the simulta-
neous binding of ubiquinone and NADH, and therefore propose that binding occurs via the one site ping-pong 
reaction mechanism. The binding pattern of ubiquinone that was observed in the previous study28 was similar to 
that observed with myxothiazol—one of the mixed-type inhibitors in the present study (Fig. 1F)—but was totally 
different from that observed at both the UQI and UQII sites in the crystallographic study by Feng et al., (Fig. 1C)29. 
On the other hand, STG-1a, to which the competitive inhibitor stigmatellin specifically binds, overlaps with the 
UQI site (Fig. 6C). Collectively, it is suggested that the ubiquinone binding site observed in our previous study 
may not represent the functional substrate binding site. The results of the present study are more consistent 
with those reported by Feng et al., which are compatible with either two-site ping-pong or ternary complex 
Interacting structure Km (μM) Vmax (μmol/min/mg)
Wild type — 22.7 ± 1.0 1060 ± 6.1
L444D
aliphatic tail of STG-1a
37.6 ± 3.9 447 ± 6.8
L444N 23.9 ± 2.0 1333 ± 14
I459A 40.2 ± 4.1 2.90 ± 0.0042
I459N 30.3 ± 2.0 11.1 ± 0.096
I459W 75.6 ± 12 58.0 ± 1.5
W63F
aromatic head of STG-1a and STG-1b
53.1 ± 6.4 1450 ± 27
P92A 25.6 ± 2.2 11.3 ± 0.4
A393G 32.5 ± 1.9 882 ± 7.6
Q394G 30.8 ± 3.4 452 ± 8.1
Q394A 24.5 ± 1.7 391 ± 3.3
H397A 35.0 ± 2.7 463 ± 17
L447N 17.9 ± 1.8 140 ± 7.1
Y482F 23.3 ± 2.0 1090 ± 45
M485A 18.6 ± 1.1 292 ± 9.9
M485E 63.5 ± 7.8 1190 ± 96
L487A 16.4 ± 2.2 424 ± 29
S484F
aliphatic tail of STG-1b
24.5 ± 3.9 1160 ± 120
S484I 25.0 ± 1.7 1010 ± 33
R479I
STG-2
27.7 ± 1.2 0.313 ± 0.007
R479A 11.5 ± 0.58 316 ± 6.1
R479K 9.37 ± 0.48 305 ± 5.8
R479H 23.5 ± 1.4 1.06 ± 0.035
Table 2. Kinetic parameters of the oxidoreductase activity of wild-type and mutant Ndi1 for ubiquinone-1.
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mechanisms. Ubiquinone-2 was used for co-crystallization in our previous study, while ubiquinone-4, which is 
more hydrophobic than ubiquinone-2 and more relevant to the ubiquinone that exits in the yeast cells, was used 
in the study by Feng et al.29. The difference in the hydrophobicity of ubiquinone derivatives might have caused the 
difference in the identification of the ubiquinone binding sites in these two studies.
In conclusion, the present study identified the first competitive inhibitor of the yeast Ndi1. The cocrystal struc-
ture of Ndi1 in complex with this competitive inhibitor and the biochemical studies with the mutants of Ndi1 in 
the relevant amino acid residues revealed the binding site for the inhibitor, which provides the structural basis for 
the competitive nature of its inhibition of Ndi1. This STG-1a site, a competitive binding site for the inhibitor, is 
therefore suggested to represent the binding site for the substrate ubiquinone (Fig. 6E). This configuration of the 
ubiquinone binding is consistent with the hypothesis that the Ndi1-mediated oxidoreductase reaction occurs via 
either a two-site ping-pong mechanism or a ternary complex mechanism.
Material and Methods
Materials. Ubiquinone-1, stigmatellin, myxothiazol, and ascochlorin were purchased from Sigma-Aldrich 
(St. Louis, MO). AC0-12 was synthesized according to the method of 1-hydroxy-2-alkyl-4(1 H) quinolone syn-
thesis36. The MagicMedia™ E. coli Expression Medium was from Life Technologies (Carlsbad, CA). The Ultra 
Yield Flask™ was from Thomson Instrument Company (Oceanside, CA). The HisTrap HP column was from GE 
Healthcare (Buckinghamshire, England). The Econo-Pac 10DG column was from Bio-Rad (Hercules, CA). All of 
the other chemicals were of reagent grade and were obtained from commercial sources.
Purification. The Saccharomyces cerevisiae Ndi1 enzyme was essentially purified and crystallized according 
to a previously described method25,28. Detailed methods of the expression and purification of Ndi1 can be found 
as Supplementary Methods.
Site-directed mutagenesis. A detailed methods of the amino acid replacements of Ndi1 can be found as 
Supplementary Methods.
Enzyme assays and the data analysis. NADH-ubiquinone oxidoreductase activity was measured as 
described previously23. In brief, the reaction was started by adding 100 µM NADH to the enzyme mixture con-
taining 10 ng/mL Ndi1, 50 mM sodium phosphate (pH 6.0) and 1 mM EDTA, which was pre-incubated with vari-
ous concentrations of ubiquinone-1 for 1 min. The decrease in 340 nm absorbance was measured as an indication 
of the oxidation of NADH (ε = 6.22 mM−1 cm−1) with a Shimadzu UV2000 spectrophotometer (Kyoto, Japan). 
The enzymatic activity obtained with 100 µM NADH and 60 µM ubiquinone-1 in the absence of any inhibitors 
(100% activity) catalyzed the oxidation of 1,890 μmol NADH/min/mg Ndi1. The concentrations of inhibitors 
required to obtain the half-maximal inhibition (IC50) were estimated by non-linear regression dose-response 
curves. The inhibition mode of each inhibitor for ubiquinone-1 was determined by the intersection point in 
double-reciprocal plots (Fig. 2B–E). To objectively evaluate the inhibition mode, the data of the inhibition kinet-
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This equation provides two dissociation constants, one for the binary enzyme-inhibitor complex (Ki), the 
other for the ternary enzyme-substrate-inhibitor complex (αKi). The value of α ranges from 0 to infinity, and 
determines the inhibition mechanism. When the constant α shows unity, the inhibition mechanism is considered 
to be noncompetitive; when α is closer to infinity, the inhibition mechanism is considered to be competitive; 
when α is closer to 0, the inhibition mechanism is considered to be uncompetitive.
To determine the kinetic parameters of wild-type and mutant enzymes for ubiquinone-1, the NADH oxidation 
rates were measured in a fixed concentration of NADH (100 µM) and different concentrations of ubiquinone-1 
(2.4–60 µM). Apparent Km and Vmax values were obtained by fitting a data set of initial velocity versus substrate 
concentration to the Michaelis-Menten model equation in the Prism6 software program.
Crystallization. The purified Saccharomyces cerevisiae Ndi1 enzyme was essentially crystallized according to 
a previously described method28 by the hanging-drop vapor diffusion method. Crystals of the Ndi1-stigmatellin, 
Ndi1-AC0-12, and Ndi1-myxothiazol complexes were prepared by co-crystallization in the presence of 1 mM 
inhibitors. The protein solution (10 mg/ml, 20 mM Mops-KOH pH 7.0, 5% (v/v) glycerol, 0.02% (w/v) DDM, 
1 mM inhibitor) was mixed with an equal volume of the reservoir solution (50 mM Mes-NaOH pH 6.2, 43% (v/v) 
PEG400, 100 mM NaCl, 2% (v/v) ethylene glycol, 5% (v/v) glycerol) and incubated at 20 °C. The crystals reached 
maximum dimensions of 0.3 × 0.2 × 0.05 mm3 in complex with AC0-12 and in complex with myxothiazol; this 
size was almost the same as that of the previously reported crystals28. The crystals in complex with stigmatellin 
were thin triangles with maximum dimensions (one side) of 0.3 mm and a thickness 0.05 mm.
Data collection and phasing. A crystal was scooped up from a hanging droplets using a cryo-loop and 
was flash-frozen in liquid nitrogen gas. The X-ray diffraction data of the Ndi1-stigmatellin and Ndi1-AC0-12 
complex crystals were collected at −173 °C on beamline BL44XU at SPring-8 (Harima, Japan) and that of the 
Ndi1-myxothiazol crystal was collected at −173 °C on beamline BL17A at Photon Factory, the High Energy 
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Accelerator Organization (Tsukuba, Japan). All of the diffraction data sets were processed and scaled with the 
HKL2000 program package37, as shown in Table S1. The determination of the structure was carried out by molec-
ular replacement with Molrep in the CCP4 software program38 using the atomic model of the ligand-free Ndi1 
structure (PDB code: 4G9K) as a search model.
Refinement. The model structures of Ndi1-stigmatellin, Ndi1-AC0-12 and Ndi1-myxothiazol were refined 
using Refmac5 in the CCP4 software program39 at resolutions of 1.85, 3.4 and 3.2 Å, respectively. Further refine-
ment and model rebuilding were performed using Refmac5 and COOT40. The crystal of Ndi1-stigmatellin con-
tains one Ndi1 and two bound stigmatellin molecules in the asymmetric unit. Crystals of Ndi1-AC0-12 and 
-myxothiazol complexes contain one dimer molecule in each of the asymmetric units. All structures were 
refined to final Rwork/Rfree values of 0.158/0.192 (Ndi1-stigmatellin), 0.207/0.299 (Ndi1-AC0-12), and 0.220/0.285 
(Ndi1-myxothiazol), respectively. The results of the structure determination are summarized in Table S1. The 
figures showing the protein structures were prepared with the PyMol software program (http://www.pymol.org/).
Data Availability. The atomic coordinates and structural factors have been deposited in the Protein Data 
Bank, www.pdb.org (Ndi1-stigmatellin, 5YJW; Ndi1-AC0-12, 5YJY; and Ndi1-myxothiazol, 5YJX).
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